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Epidemiology and Clinical Impact of Glycopeptide 
Resistance in Staphylococcus aureus
C. Ruef
Abstract
Staphylococcus aureus with resistance to glycopeptide 
antibiotics has been considered to be a rare cause of clini-
cally relevant infections. A review of the current literature 
shows that this is indeed the case for infections caused 
by S. aureus with high-level resistance to vancomycin 
(VRSA), as only isolated cases have been reported. VRSA 
develops following the insertion of the vanA gene, which 
is transferred from enterococci with vancomycin resis-
tance. On the other hand, infections caused by S. aureus 
with intermediate resistance to glycopeptides (VISA), or 
heterogeneously expressed intermediate level glycopeptide 
resistance (hVISA), are more common. These infections are 
associated with clinical failure of glycopeptide therapy. 
While the biochemical and phenotypic features including a 
thickened cell wall of hVISA and VISA are well known, the 
genetic basis of these phenotypes remains unknown. Certain 
genetic regulatory elements such as agr II are associated 
with reduced susceptibility of S. aureus to glycopeptides. 
Available data suggest that certain infections might be 
successfully treated using higher doses of vancomycin. 
However, as treatment failure is particularly common in 
infections with a high bacterial load, it may be necessary to 
resort to other antibiotics such as linezolid, often combined 
with surgical intervention, in order to successfully treat 
these infections. Open questions regarding diagnosis, patho-
genesis, epidemiology, and treatment of glycopeptide resis-
tance in S. aureus are addressed in this review. Clinicians 
should be aware of these aspects, since S. aureus remains 
one of the most important bacteria in modern medicine.
Infection 2004; 32: 315–327
DOI 10.1007/s15010-004-4124-7 
Introduction
Infections caused by antibiotic-resistant bacteria are a 
growing problem in many geographic areas [1]. Hospi-
talized patients as well as outpatients are affected by this 
problem [2]. In adult outpatients, the prevalence of resis-
tance of Escherichia coli to aminopenicillins or quinolones, 
of Streptococcus pneumoniae to penicillin or macrolides, 
and of Streptococcus pyogenes to macrolides is relatively 
high in various geographic areas [3]. Similarly, antibiotic 
resistance of S. pneumoniae, S. pyogenes, Haemophilus in-
fluenzae, and Moraxella catarrhalis has become a clinically 
relevant concern regarding the treatment of infections in 
children in most countries [4], whereas Staphylococcus au-
reus has typically been susceptible to antibiotics that are 
used to treat infections in the outpatient setting. Follow-
ing the emergence of community-acquired methicillin-re-
sistant Staphylococcus aureus (MRSA), this susceptibility 
can no longer be assumed in several areas of the world [5]. 
Infections caused by antibiotic-resistant bacteria may have 
a protracted or even lethal course [6, 7].
S. aureus is probably one of the most common patho-
gens in outpatient as well as hospital medicine. Infections 
caused by S. aureus may be relatively mild and easy to 
treat, or may take a dramatic, and at times life-threaten-
ing course, as is illustrated by numerous case reports and 
studies [8,9]. In addition to S. aureus, other staphylococ-
cal species such as Staphylococcus lugdunensis have a high 
pathogenic potential due to the expression of binding fac-
tors and may cause severe infections such as rapidly de-
structive endocarditis [10, 11]. 
Antibiotic resistance in S. aureus may have negative 
consequences in several areas of medicine. Probably the 
most visible consequence of the increased  resistance is 
seen in the clinical management of individual patients with 
infections caused by resistant S. aureus. Methicillin resis-
tance of S. aureus will force clinicians to resort to antibiot-
ics such as vancomycin that are less bactericidal, or more 
slowly bactericidal than betalactam antibiotics such as naf-
cillin [12]. The in vitro observation of a reduced bacteri-
cidal effect of vancomycin is clinically relevant, as has been 
shown in a prospective study of the treatment of bacte-
remia caused by methicillin-susceptible S. aureus (MSSA) 
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[13]. In this study, the relapse rate following treatment with 
vancomycin was significantly higher than the correspond-
ing rate after treatment with nafcillin. 
Several years ago, the problem of antibiotic resistance 
of S. aureus was accentuated by the appearance of clini-
cal infections caused by strains that exhibited resistance to 
glycopeptides [14–16]. A series of investigations has shown 
that glycopeptide resistance of S. aureus is not a “yes-no” 
phenomenon, but includes intermediate levels of resistance 
as well as strains, which upon more detailed investigation 
are heteroresistant.
This review will summarize the current epidemiology 
of glycopeptide resistance in S. aureus, its trends, and will 
focus on clinical issues such as diagnosis and treatment of 
infections caused by S. aureus with heteroresistance, inter-
mediate or complete resistance to glycopeptides. Further-
more, published experiences on modes of transmission of 
these bacteria in the hospital and in the outpatient setting, 
as well as preventive measures will be summarized.
Categories of Glycopeptide Resistance
Reduced susceptibility to vancomycin has been reported 
repeatedly over the course of the last few years. The NC-
CLS defines S. aureus isolates with vancomycin MICs be-
tween 8 and 16 µg/ml as intermediately sensitive, and iso-
lates with a MIC of ≥ 32 µg/ml as resistant, whereas in Japan 
the breakpoint for resistance is ≥ 8 µg/ml [17]. Similarly, 
British and Swedish definitions do not include a category 
of intermediate susceptibility to vancomycin or teicoplanin 
(Table 1) [18]. Strains of S. aureus with a heterogeneous 
population regarding the susceptibility to vancomycin are 
termed heterogeneous vancomycin (or glycopeptide) inter-
mediate S. aureus (hVISA or hGISA) [18].
Hiramatsu et al. [19], who were first to report a het-
eroresistant clone, labeled Mu3, defined a S. aureus strain 
as heteroresistant, if subclones with a vancomycin MIC of 
≥ 8 µg/ml were produced upon selection with vancomycin. 
Such strains had to remain stable at least 9 days in a drug-
free medium. More recently, Walsh and Howe modified the 
definition of heteroresistance by requiring that population 
heterogeneity should be demonstrated in a full population 
analysis profile [18]. According to these authors, a S. aureus 
isolate is defined as heteroresistant to vancomycin, if the 
ratio of the areas under the population analysis curve of the 
isolate in question and of the Mu3 control strain is ≥ 0.90.
This laborious diagnostic approach is not practical for 
routine microbiology laboratories. On the other hand, the 
sensitivity of the broth microdilution method is insufficient 
to reliably detect hGISA [20, 21]. The Etest method with a 
large inoculum (no. 2 McFarland standard) and an extended 
incubation time (48 h) was found to be a sensitive screening 
method for the detection of glycopeptide resistance [22]. 
However, low rates of false-positive results – 1.6% [20] 
and 2.1% [22] – have been reported. The sensitivity and 
specificity of Etest screening on brain heart infusion agar 
using 2.0 McFarland inocula and a breakpoint of ≥ 8 µg of 
vancomycin per ml compare favorably to other methods as 
shown in table 2 [22]. Current CDC recommendations are 
not based on the use of a high inoculum. The proposed al-
gorithm for testing of S. aureus regarding vancomycin sus-
ceptibility starts with either a nonautomated MIC method 
(reference broth microdilution, agar dilution, or Etest us-
ing a 0.5 McFarland standard inoculum on Mueller-Hinton 
agar), or with disk diffusion combined with a vancomycin 
screen plate (BHIA with 6 µg/ml of vancomycin) [23]. A 
comparison of methods used in published studies to diag-
nose heteroresistance of S. aureus to glycopeptides shows 
that definitions and conditions for laboratory detection of 
hGISA are not standardized. This may result in an under-
estimation of the true prevalence of such strains among 
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   Vancomycin    Teicoplanin
Organization Susceptible Intermediate Resistant Susceptible Intermediate Resistant
NCCLS ≤ 4 8–16 ≥ 32 ≤ 8 16 ≥ 32
SFM ≤ 4 8–16 ≥ 32 ≤ 4 8–16 ≥ 32
BSAC, SRGA ≤ 4 – ≥  8 ≤ 4 – ≥   8
NCCLS: National Committee for Clinical Laboratory Standards; SFM: Société Française de Microbiologie; BSAC: British Society for Antimicro-
bial Chemotherapy; SRGA: Swedish Reference Group for Antibiotics
Table 1
Breakpoints (µg/ml) for MIC testing of S. aureus.
Method Sensitivity (%) Specificity (%)
Agar dilution 20 100
Broth dilution 11 100
Mueller-Hinton screening 20 99
BHI screening 22 97
Simplified population 
screening 71 88
Etest, 0.5 McFarland 82 93
Etest 2.0 McFarland 96 97
Table 2
Sensitivity and specificity of various methods to detect heterore-
sistance or intermediate resistance to vancomycin in MRSA [22].
clinical isolates of S. aureus [24], and renders comparison 
of epidemiological data difficult.
While the Etest with a higher inoculum appears to 
improve the sensitivity of the diagnostic approach to het-
eroresistance in S. aureus, care must be taken to avoid the 
artificial elevation of the vancomycin MIC by serial pas-
sage of the bacteria on media containing vancomycin. This 
effect was already described in the mid-1950s, as pointed 
out by Moellering [25]. Despite recent progress in labora-
tory approaches, detection of heteroresistant S. aureus in 
the routine clinical microbiology laboratory remains a dif-
ficult challenge, as definitive proof still requires population 
analysis profiling [19].
Pathogenesis
The pathogenesis of resistance of S. aureus to glycopep-
tides is not fully understood. Except for rare cases, reduced 
susceptibility to glycopeptides is not found in MSSA. So 
far, a single case of MSSA with heteroresistance to gly-
copeptides has been reported [26, 27]. The genetic events 
resulting in phenotypic expression of resistance appear to 
be different in strains with high-level vancomycin resis-
tance compared with strains exhibiting intermediate levels 
of resistance (Table 3). S. aureus with reduced susceptibil-
ity to vancomycin has a thick cell wall in comparison to 
susceptible S. aureus [28], whereas vancomycin-resistant 
S. aureus is resistant as a result of the acquisition of the 
vanA gene from vancomycin-resistant enterococcus [29]. 
This gene is then integrated into a S. aureus conjugative 
plasmid. Vancomycin resistance is only expressed when 
the bacterial cell is exposed to vancomycin [30]. In addi-
tion, vancomycin- and methicillin-resistance may be co-
expressed in VRSA strains, suggesting that resistance may 
also occur in the absence of selection pressure caused by 
vancomycin use [31].
In S. aureus with intermediate resistance to glycopep-
tides, cell-wall thickness plays a major role in mediating 
resistance. As reviewed by Hiramatsu [32], the first clinical 
S. aureus strain with reduced susceptibility (Mu50) has 30–
40 layers of peptidoglycan compared to approximately 20 
layers in fully susceptible strains. The increased number of 
layers in VISA contains many D-alanyl-D-alanine targets 
to which glycopeptide molecules can bind (affinity trap-
ping), thus resulting in a reduced access of glycopeptides to 
their site of action, namely the D-alanyl-D-alanine residues 
of murein monomers, which are located in the cytoplasmic 
membranes, and are ready to be used in peptidoglycan syn-
thesis. If the glycopeptides bind to these monomers, pep-
tidoglycan synthesis, and as a consequence cell multiplica-
tion, is completely inhibited [32]. Penetration of glycopep-
tides to their site of action in the cytoplasmic membrane is 
further inhibited by the destruction of the mesh structure 
of the outer layers of peptidoglycan by the trapped glyco-
peptide molecules themselves. This event was described as 
“clogging phenomenon” by Cui et al. [33].
The genetic basis for the regulation of cell-wall thick-
ness in S. aureus is currently not known. The presence of 
vancomycin or beta-lactams in the bacterial environment 
appears to influence this phenotypic expression. In a re-
cent review, Hiramatsu [32] favored the hypothesis that 
heteroresistant VISA is a precursor to VISA and that these 
two phenotypes are expressed dependent on the selection 
pressure of vancomycin. This concept is illustrated in fig-
ure 1, which is adapted from Hiramatsu’s review. Further 
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Type of resistance Genetic event Biochemical and phenotypic effects Reference
VRSA Acquisition of vanA gene  Replacement of the carboxy terminal D-alanyl-  Weigel [29]
 (transposon Tn1546) from D-alanine of the peptidoglycan cell wall precursor 
 vancomycin-resistant  by D-alanyl-D-lactate; resulting in a 1,000-fold lower  
 Enterococcus faecalis affinity to vancomycin
hVISA, VISA Unknown Thickening of cell wall secondary to: Hiramatsu [32]
  · Increased production of peptidoglycan
  · Reduced turnover of peptidoglycan
  Resulting in:
  · Affinity trapping of vancomycin
  · Clogging phenomenon by trapped vancomycin
  · Raised proportion of D-alanyl-D-alanine residues in 
     peptidoglycan layers further increasing trapping of vancomycin
Table 3
Pathogenesis of glycopeptide resistance in S. aureus.
VSSA Heteroresistant VISA VISA
Unstable Stable
Vancomycin or beta-lactam
Vancomycin
Figure 1.  Phenotypic stages of MRSA dependent on presence or ab-
sence of selection pressure by vancomycin or beta-lactam antibiotics 
(adapted from [32]).
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research will be needed in order to assess the validity of 
this hypothesis.
Regulation of resistance to vancomycin is probably un-
der the control of several genes. Among these, downregu-
lation of tcaA, which encodes a transmembrane protein, 
was associated with increased glycopeptide resistance in S. 
aureus [34]. Another regulatory gene, the accessory gene 
regulator (agr) of S. aureus also appears to play a role in the 
expression of glycopeptide resistance. This gene occurs in 
four groups. Sakoulas et al. [35] have recently shown that 
agr group II was more prevalent in blood culture isolates 
of MRSA than MSSA. The authors performed population 
analysis of genetically engineered agr-null S. aureus strains 
and were able to show that glycopeptide heteroresistance 
is associated with loss of agr function. In an earlier study, 
the authors showed that GISA and hetero-GISA strains 
from the United States and Japan belonged to agr group II 
and that many GISA isolates were defective in agr function 
[36]. Based on these and other studies, Walsh and Howe 
[18] hypothesize that mutations in agr and/or sar, another 
regulatory locus of S. aureus, or altered expression of these 
regulators, may lead to a VISA or hVISA phenotype. 
Epidemiology of Glycopeptide Resistance
Infections caused by S. aureus with high-level resistance to 
vancomycin are rare. Only three cases have been reported 
so far [37–41]. All three patients had underlying diseases, 
had received antibiotics, and were reported from the USA. 
Coinfection with MRSA and VRE was present.
Intermediate resistance of S. aureus to vancomycin is 
clearly more common than high-level resistance. At least 
20 cases of VISA infections have been reported from vari-
ous continents [18]. Pretreatment with vancomycin was a 
common feature in many of these patients [42, 43].
The prevalence of S. aureus with heteroresistance to 
glycopeptides appears to be higher than the corresponding 
prevalence of VISA. Several studies have been conducted 
in Europe (France [27, 44–49], Germany [50, 51], Italy [52], 
Netherlands [20], Spain [53], United Kingdom [54, 55]), 
Asia – Hong Kong [56], Japan [19, 57, 58], Korea [59, 60]), 
South America – Brazil [61]), and North America – USA 
[62–64]). Reported prevalence rates vary greatly between, 
as well as within continents (Table 4). These results should 
be interpreted with caution, as methods to screen for and to 
diagnose hVISA varied widely from study to study. 
In many other areas the prevalence of vancomycin re-
sistance appears to be low. A recent prevalence survey of 
more than 1,000 MRSA isolates in Belgium found only one 
homogeneous vancomycin-resistant S. aureus (VISA) and 
five heterogeneous VISA (hVISA) based on population 
analysis profiling [65]. In a Brazilian study of 140 MRSA 
isolates, five S. aureus with reduced susceptibility to vanco-
mycin (MIC 8 µg/ml) were found [66]. None were positive 
for vanA and all had thickened cell walls.
The Netherlands have a very low prevalence of 
MRSA. As heteroresistance to vancomycin appears to be 
associated with vancomycin use to treat MRSA infections, 
heteroresistance would not be expected to be prevalent in 
countries with such a low prevalence of MRSA. However, 
van Griethuysen et al. [20] reported a rate of 6% of het-
eroresistance to vancomycin in MRSA strains. Epidemio-
logical information on the origin of the affected patients 
revealed that none of the isolates originated the Nether-
lands. The patients were in Turkey, Greece, Italy, France, 
Germany, and the Ivory Coast.
Risk Factors for Glycopeptide Resistance
According to the hypothesis of Hiramatsu [32] (Figure 1), 
use of glycopeptides or beta-lactam antibiotics is a major 
driving force of glycopeptide resistance in S. aureus. In-
deed, the analysis of published cases of infections caused 
by VISA or hVISA reveals that the majority of patients has 
a history of pretreatment with glycopeptides and/or beta-
lactams. However, in patients with hVISA, vancomycin 
was often used to treat the infectious episode during which 
hVISA was recognized. This observation also supports Hi-
ramatsu’s concept of an induction of an unstable or stable 
phenotype of hVISA by ongoing glycopeptide therapy.
As glycopeptides are the first choice of clinicians for 
the treatment of infections caused by methicillin-resistant 
staphylococci, the use of these agents (vancomycin, tei-
coplanin) is fairly widespread. In a 3-year survey of eight 
German university hospitals, performed between 1998 and 
2000, Kern et al. [67] registered an average glycopeptide 
use ranging between 1.3 and 8.8 DDD/100 patient days on 
medical wards, whereas the corresponding use on surgical 
wards ranged between 0.7 and 1.8 DDD/100 patient days. 
Compared to an earlier survey [68], which was performed 
in four of these hospitals, glycopeptide use on surgical 
wards was lower in some hospitals, probably as a result 
of an active antibiotic management program. Glycopep-
tide use was markedly higher in intensive care units and 
hematology-oncology units, ranging up to 15.7 DDD/100 
Geographic area Prevalence rate (range, %)
Europe 0–27a
Asia 0–26b
Brazil 3
USA 0–3.1
aMost studies from Europe reported rates between 0 and 5%. A 
high rate of 27% was found in liver transplant recipients infected 
or colonized with MRSA [49]. bConflicting results were reported 
from Japan. While Hiramatsu reported a prevalence rate of 26% 
in four university hospitals, where the study was conducted in 
1996 [19], Ike failed to detect any heterogeneously or intermedi-
ately resistant strains among 6,625 clinical MRSA isolates collect-
ed in 278 hospitals throughout Japan during 1997 [58].
Table 4
Geographic variation of the prevalence of heteroresistance to 
vancomycin in S. aureus.
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patient days. There was a striking variation in glycopeptide 
use between hospitals, which did not correlate with differ-
ences in the prevalence of endemic MRSA. Differences in 
glycopeptide use between medical, surgical, and intensive 
care units were also observed in an Italian point prevalence 
survey of antibiotic consumption in 15 hospitals in 2001 
[69], and in another German survey of antibiotic use in 
ICUs, with lower use rates in medical compared to surgi-
cal ICUs [70].
Anecdotal reports of the development of heteroresis-
tance to vancomycin in MRSA during prolonged vanco-
mycin therapy suggest that the prevalence of heteroresis-
tant VISA may increase in institutions with a high use of 
vancomycin [24]. Heteroresistance to vancomycin may also 
be induced by the treatment of MRSA infections with a 
cephalosporin in combination with vancomycin, as seems 
to be a common practice in Japan [71].
Antibiotic use is not only a concern in adult patients. 
A recent study by Potocki et al. [72] showed that 36% of 
hospitalized children received antibiotics during their stay. 
Overall, 15% of antibiotic use was judged inappropriate.
While antibiotic resistance in S. aureus is a major 
problem in many European countries, resistance in other 
bacterial species should also be considered, as exchange of 
resistance plasmids has been observed. Linezolid is a valid 
alternative to vancomycin, and might be one of the few 
remaining antibiotics with activity against vancomycin-re-
sistant S. aureus. However, transfer of linezolid resistance 
from enterococci to S. aureus may result in linezolid re-
sistance in S. aureus as well. Clinically relevant linezolid 
resistance has been reported in isolated cases [73]. Surveil-
lance of antibiotic resistance should therefore also include 
surveillance of linezolid resistance in gram-positive cocci 
in general.
In addition to glycopeptide or beta-lactam use, other 
clinically relevant risk factors for the development of gly-
copeptide resistance in S. aureus are frequently present. 
These are summarized in table 5. A high bacterial load in-
fection in a patient with a serious underlying disease, who 
is receiving glycopeptide treatment for a MRSA infection 
at dosages that result in low concentrations, is probably 
the prototype scenario for the emergence of the hVISA or 
VISA phenotype during therapy. 
Clinical Impact of Glycopeptide Resistance
Resistance to antibiotics does not necessarily result in a 
worse outcome, as has been demonstrated in several stud-
ies. There was no correlation between inappropriate an-
tibiotic treatment as a result of resistance and mortality 
in patients with Citrobacter freundii bacteremia [74]. This 
unexpected observation can be explained by the presence 
of underlying diseases and other clinical parameters, which 
also have a major impact on outcome.
Therefore, adjustment for confounding variables 
needs to be made when comparing outcomes of infections 
caused by resistant or susceptible bacteria. The treatment 
of MRSA infections is already difficult, since only a limited 
number of antibiotics are active against MRSA. A meta-
analysis of studies examined the difference in mortality 
between MRSA and methicillin-susceptible S. aureus bac-
teremia [8]. The pooled risk of death from MRSA bacter-
emia for all 31 studies was almost 2-fold higher than the 
risk of dying from MSSA bacteremia.
MRSA infections are particularly difficult to treat, if 
they are located at anatomical sites, where antibiotic pen-
etration is reduced, such as the central nervous system. 
Bacterial meningitis caused by MRSA was associated with 
a mortality rate of 56%, compared to a mortality rate of 
13% in a patient group with meningitis caused by methi-
cillin-susceptible S. aureus [75]. All patients with MRSA 
infections were treated with vancomycin, which penetrates 
poorly into the cerebrospinal fluid. In several patients with 
MRSA vertebral osteomyelitis treatment with vancomycin 
failed to eradicate the infection [76]. All isolates had MICs 
to vancomycin of 1 µg/ml or less by routine susceptibil-
ity testing; however heteroresistance was not excluded. In 
addition to pharmacokinetic reasons, the presence of het-
eroresistance to S. aureus should be considered in these 
patients, since all had received several weeks of vancomy-
cin treatment prior to the culture, which documented treat-
ment failure.
Clinical failures have been reported in patients with 
infections caused by VISA or hVISA [43, 77]. Accessory 
gene regulator group II polymorphism in MRSA has been 
found to be an independent predictor of vancomycin treat-
ment failure [78]. How this polymorphism leads to vanco-
mycin failure is currently not known. However, treatment 
failure may not always be caused by the resistance prob-
lem, but may be the result of clinical circumstances, such 
as an undrained abscess. The true clinical relevance of het-
eroresistance or intermediate resistance to glycopeptides 
in S. aureus still remains a matter of debate. Outcomes of 
Risk factor Reference
Glycopeptide use 
· Widespread use: selection pressure Hiramatsu [32] 
· Low tissue concentration Charles [79]
· Vancomycin treatment failure Charles [79]
Underlying disease Howden [82]
· Diabetes mellitus
· Immunosuppression
· Malignancy
· End-stage renal failure
· Surgery within 8 weeks before hVISA detection
High bacterial load infection Charles [79], 
· Endocarditis Ariza [53]
· Abscess
· Orthopedic device infection
Table 5
Risk factors for infections caused by hVISA or VISA.
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published cases vary greatly. Many reports do not provide 
sufficient details to assess the role of the infection itself, 
or of the antibiotic treatment in the clinical course of indi-
vidual patients.
Infections caused by heteroresistant VISA are associ-
ated with a protracted clinical course, as has been shown 
in a study of hVISA bacteremia, which persisted for 7 days 
more in a larger proportion of patients than did MRSA 
bacteremia [79]. Therefore, reduced susceptibility to van-
comycin should be suspected in patients with MRSA in-
fection that does not improve despite adequate vancomy-
cin levels [80]. In a study of  22 patients with persistent 
or recurrent MRSA bacteremia, heteroresistance to van-
comycin was found in three (13.6%) isolates, suggesting 
that heteroresistance may be a relevant cause of treatment 
failure [81].
Treatment Options for hVISA or VISA 
At least some of the reported cases appear to demonstrate 
a favorable clinical response to vancomycin treatment. 
However, a recent study by Howden et al. [82] showed that 
glycopeptide therapy failed for 76% of the patients. Only 
ten out of 21 patients were cured using other antibacterial 
agents, and 60% of the patients required surgery. It there-
fore appears prudent to aim for higher serum trough van-
comycin levels (15–20 µg/ml) during treatment of hVISA 
infections, even though the MIC of vancomycin for most 
strains that were identified as VISA or hVISA is well be-
low the serum levels, which are normally achieved during 
treatment with vancomycin [83]. It must also be kept in 
mind that achievable vancomycin concentrations in certain 
anatomical locations such as the lung or in abscesses are 
markedly lower than the corresponding serum concentra-
tions [84, 85].
As recurrent episodes of hVISA bacteremia have been 
reported despite adequate serum vancomycin levels [56, 
86], other treatment options are needed to treat refractory 
infections. Among these, quinupristin/dalfopristin has 
been studied clinically in various settings. A recent report 
documented that this antibiotic can be successfully used to 
treat severe MRSA infections in patients with end-stage 
renal insufficiency [87]. However, its penetration into the 
CSF is very limited [88]. There are no reports describing 
the efficacy of quinupristin/dalfopristin for the treatment 
of hVISA or VISA infections. 
Linezolid has been used successfully to treat meningi-
tis [89-91], as well as osteomyelitis caused by MRSA [92]. 
It has also been used successfully to treat hVISA infections 
after vancomycin failed [82]. Median duration of treatment 
was 41 days.
Antibiotic combinations may be another option to ap-
proach clinical failures due to hVISA or VISA. In a non-
controlled, observational study of five patients with meth-
icillin-resistant S. aureus or coagulase negative staphylo-
coccal infections who had previously failed treatment with 
vancomycin, the combination of quinupristin/dalfopristin 
with a glycopeptide resulted in clinical cure in four patients 
[93]. In vitro testing of most bacterial isolates revealed syn-
ergy between quinupristin/dalfopristin and teicoplanin.
In their study of treatment outcomes in hVISA infec-
tions, Howden et al. [82] used the combination of rifampicin 
and fusidic acid following clinical control of the infection 
by linezolid. One patient with bacteremia and septic arthri-
tis caused by a hVISA isolate with resistance to rifampin 
was treated with fusidic acid and chloramphenicol after 
initial treatment with linezolid. Wong et al. [86] reported 
a favorable clinical response in a patient with bacteremia 
after adding fusidic acid to the regimen. Based on in vi-
tro checkerboard testing, these authors also demonstrated 
synergy between ampicillin and vancomycin, despite the 
fact that over 90% of staphylococci studied were producers 
of penicillinase. Heym et al. [94] treated five patients with 
infections caused by S. aureus with intermediate resistance 
to teicoplanin, using a combination of vancomycin, fusidic 
acid, and chloramphenicol (three patients, all cured), or 
with vancomycin combined with fusidic acid, or vancomy-
cin alone (one patient each).
An in vitro study of vancomycin combined with ceph-
alosporins in a clinical isolate of S. aureus that exhibited 
heteroresistance to vancomycin (MIC < 8 µg/ml), yielded 
nonconclusive results regarding the inhibitory effect of 
such a combination [95]. Although no randomized, clinical 
studies of the treatment of infections caused by hVISA or 
VISA have been conducted, currently available data sug-
gest that linezolid may be a good alternative to vancomy-
cin or teicoplanin for the treatment of these infections. As 
isolated cases of linezolid-resistant MRSA or VRE have 
been reported, this new therapeutic agent should be used 
judiciously to preserve its clinical activity [96–98].
Treatment options are even more limited for infec-
tions caused by S. aureus with resistance to vancomycin. 
The vancomycin MIC of the Michigan isolate [37] was 
1,024 µg/ml and the strain was also resistant to aminoglyco-
sides, beta-lactams, fluoroquinolones, macrolides, rifampin, 
and tetracycline [29]. This scenario is threatening and must 
be addressed in a comprehensive fashion in order to limit 
its clinical and public health consequences [99, 100]. 
Infection Control Issues
Modes of Transmission of VISA and hVISA 
S. aureus with heteroresistance to vancomycin may cause 
outbreaks, as has been shown by Cassone et al. [101], who 
described the transmission of a clone among patients and 
healthcare workers in a cardiac surgery ICU. This clone 
was genetically related to a previously known MRSA clone. 
Other authors also provide some circumstantial evidence 
for the nosocomial transmission of such strains (Table 6). It 
seems probable that the same modes of transmission apply 
to these strains, which are well described for MRSA. How-
ever, no studies have examined the biological behavior of 
VISA and hVISA regarding transient hand colonization 
of healthcare workers (HCW), nasal and skin colonization 
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of patients and HCW, survival of these strains on environ-
mental surfaces, degree of environmental contamination 
related to patients with colonization or infection by these 
phenotypes of S. aureus.
Infection Control Measures 
Given the pathogenetic model of phenotypic transition 
from VSSA to hVISA and eventually VISA under anti-
biotic selection pressure, it follows that reduction of gly-
copeptide or beta-lactam use is a central and crucial mea-
sure to reduce the risk for an increase in the prevalence 
of hVISA and VISA [32]. Perioperative antibiotic pro-
phylaxis is one of the major indications for antibiotic use. 
Guidelines for the use of antibiotics in this setting exist and 
are used by many hospitals. Most guidelines recommend 
first or second-generation cephalosporins for the majority 
of indications of perioperative antibiotic prophylaxis. This 
recommendation may need to be revised in settings with a 
very high rate of MRSA. Despite existing guidelines, which 
recommend applying prophylaxis as a single dose, misuse 
of antibiotics in this setting is fairly common. A survey of 
German hospitals found that prophylaxis was limited to 
a single dose in less than half of the procedures [102]. As 
both the prophylactic and therapeutic use of antibiotics will 
exert a selective pressure on the bacterial flora of exposed 
patients, it will be important to improve the prophylactic 
use of antibiotics in order to reduce the risk of resistance 
development in the hospital setting [103]. A recent report 
of a patient with community-acquired pneumonia caused 
by a levofloxacin-resistant S. pneumoniae illustrates the 
clinical relevance of any use of antibiotics, as this may re-
sult in inadvertent development of resistance in bacteria, 
which were not the target of the antibiotic prescription 
[104]. Similarly, a Dutch study found a parallel increase in 
the prevalence of quinolone-resistant E. coli and in the use 
of fluoroquinolones among Dutch outpatients [105].
In addition to efforts to curtail misuse of antibiotics in 
the hospital, it will be important to apply a comprehensive 
strategy to reduce the total number of MRSA. Accord-
ing to Hiramatsu [32], this is the most effective measure 
for preventing emergence of VISA and hVISA. Cosgrove 
et al. [17] recently reviewed the CDC recommendations 
for infection control for patients infected or colonized 
with S. aureus with decreased susceptibility to vancomy-
cin. These recommendations (isolation in a private room, 
gowns, gloves to enter room, mask and eye protection if 
aerosolization is possible, hand disinfection, avoidance of 
sharing of equipment between patients, minimization of 
the number of staff caring for patient, staff education) do 
not differ from measures recommended to prevent trans-
mission of MRSA. In addition to these measures, the CDC 
recommends to perform weekly screening of the nares of 
Country Setting          No. of  Glycopeptide Remarks
[Reference]   patients involved pretreatment
France [126] Acute care and                15 None 11 patients from LTCF (10 nasal colonization,
 long-term care    1 UTI), 3 from ICU (pulmonary infection); 
 facility (LTCF)   2 genotypes by PFGE.
Italy [52] Rehabilitation unit                 2 2 Epidemiological evidence suggestive of 
    transmission. However, genetically related  
    MRSA clone is widely disseminated in several  
    units.
France [127] Acute care               39 Unknown High degree of genetic relatedness, same rare  
    lysotype, multiresistant phenotype; increase  
    in frequency over 2 month period as 
    arguments for transmission. No further data 
    to assess true rate of transmission.
France [94] Acute care                 6 1/6 Epidemiological evidence linking patients, 
    results of PFGE and multilocus sequence typing 
    suggesting transmission of MRSA with reduced  
    susceptibility to teicoplanin.
France [46] Acute care                 6 Unknown Single clone; transmission postulated without  
    giving detailed information.
France [49] Liver transplant                 13 2/13 11 strains belonging to same genetic cluster.
 recipients   Preoperative screening negative. Authors  
     conclude from this and the absence of 
    glycopeptide exposure that transmission was  
    responsible for these cases.
Table 6
Studies reporting nosocomial transmission of hVISA or VISA.
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persons with extensive patient contact [17]. In addition, 
isolates with vancomycin MICs of 4 mg/l or higher should 
be reported to local and state health authorities [17].
From a theoretical point of view, it could be hypoth-
esized that the thick cell wall of VISA and hVISA strains 
would render the bacteria relatively resistant to chemical 
or physical means of inactivation such as certain disinfec-
tants. Indeed, a recent report described a high rate (> 84%) 
of resistance to triclosan in French GISA isolates [106]. 
Increased MICs of chlorhexidine, benzalkonium chloride, 
and hexanidine di-isoethionate were also found. 
Even in high-level vancomycin-resistant S. aureus, the 
host plasmid is a multiresistance plasmid, which even con-
fers resistance to quaternary ammonium compounds [29]. 
It is currently unclear whether these in vitro observations 
are relevant and will have an impact on recommendations 
for hand, instrument, or surface disinfection. This will have 
to be determined by additional investigations. 
The Cost of Antibiotic Resistance 
Measurement of the impact of antibiotic resistance on 
healthcare costs in various countries is difficult due to 
imprecision of data about several parameters, such as re-
sistance rates, antibiotic consumption data, outcome mea-
sures, and data on the incidence of nosocomial infections 
[107]. However, as the resistance problem is growing, it 
may be necessary to include resistance data into reports 
of national surveillance systems of nosocomial infections, 
in order to assess and compare performances and risks of 
hospitals regarding these infections [108]. Such a system 
has been designed and implemented in more than 30 Ger-
man intensive care units [70, 109].
The results of some local studies provide interest-
ing information regarding the negative consequences of 
antibiotic resistance on cost. A study from Duke Uni-
versity Medical Center reported median total costs for 
nosocomial bacteremia caused by MRSA of $27,083 ver-
sus $9,661 for bacteremia caused by methicillin-sensitive 
S. aureus [110]. A systematic audit of studies describing 
economic aspects of nosocomial infections revealed that 
costs for MRSA infections were highest with a mean of 
$35,367 [111]. A large fraction of additional costs that 
are attributed to the development of a nosocomial infec-
tion results from the prolonged hospital stay, rather than 
from the use of antibiotics to treat these infections [112]. 
The distribution of cost between hospital stay and costs 
of antibiotics might be different for infections caused by 
hVISA or VISA, especially if these infections are treated 
with relatively expensive antibiotics such as linezolid. A 
comprehensive economic analysis of factors, which influ-
ence the overall cost of antibiotic resistance will be help-
ful to strengthen the argument that fighting antibiotic 
resistance is cost-effective [113]. 
Based on the analysis of published data and on an 
unpublished Canadian study, it can be estimated that 
measures to detect and prevent transmission of resistant 
pathogens will increase hospital costs by $150 to $250 per 
day [114]. Nevertheless, as has been shown by Chaix et al. 
[115], efforts to control and contain MRSA are cost-effec-
tive under most circumstances. Although not yet formally 
investigated, efforts to prevent the further spread of glyco-
peptide resistance in S. aureus are likely going to be cost-ef-
fective as well, as these efforts are essentially similar to the 
efforts for MRSA control. In order to be successful, it will 
be important to improve compliance with infection control 
measures during contact with MRSA infected or colonized 
patients, as this was found to be poor [116]. 
Open Questions and Outlook  
In order to advance our knowledge about S. aureus with 
glycopeptide resistance and to improve the management 
of patients infected by such strains, research will be needed 
in epidemiology, diagnostic microbiology, pathogenesis, 
and clinical management of glycopeptide resistance. 
As reduced susceptibility to vancomycin has been de-
tected in most pandemic MRSA strains, it appears very 
probable that this type of resistance will become a global 
problem [117]. Changes in the epidemiology of MRSA 
may precede changes in the epidemiology of hVISA and 
VISA. Intensive care units, due to the frequent use of 
antibiotics and the higher prevalence of patients with 
nosocomial infections are likely locations for the selec-
tion of heteroresistance. The prevalence of MRSA in in-
tensive care units varies markedly, even within countries. 
A survey of German ICUs found an overall prevalence of 
MRSA of 14.3% among nosocomial S. aureus infections 
[118]. However, while more than 60% of the surveyed 
units did not observe any MRSA infection, in some units 
the MRSA rate was greater than 50%. Clusters and out-
breaks were common [118]. A more recent German study, 
which is based on the surveillance of antibiotic resistance 
in more than 20,000 isolates that were obtained from pa-
tients in 35 ICUs, found methicillin resistance in 19.3% 
of S. aureus [70]. In order to obtain more precise data 
about the prevalence, clinical impact and management of 
infections caused by VISA or hVISA, adaptation of cur-
rent surveillance strategies to include active surveillance 
for VISA and hVISA in high- risk areas of the hospital 
should be considered.
As discussed above, detection of VISA and hVISA 
in clinical samples is a challenge for routine diagnostic 
laboratories. Etest with a high inoculum appears to be 
the test with the best performance, while still acceptable 
regarding workload for diagnostic laboratories. Standard-
ization of recommendations between countries is urgently 
needed in order to develop common procedures for the 
management of patients with MRSA, which may possi-
bly exhibit glycopeptide resistance. Once the genetic basis 
for VISA or hVISA is elucidated, molecular techniques 
might become available for the diagnosis of this resistance 
genotype. However, as VISA and hVISA are transient 
phenotypic states of VSSA, the sensitivity of such mo-
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lecular tools might depend on the stability of expression 
of relevant genes in these strains.
In addition to the determination of molecular mark-
ers for the hVISA or VISA phenotype, investigations of 
the link between agr II polymorphism, other regulatory 
genes, and invasiveness or other microbiological or clini-
cal features of glycopeptide resistant S. aureus will be 
important for the understanding of the pathogenesis of 
infections caused by such strains. 
Finally, more detailed clinical information is needed 
in order to assess the contribution of glycopeptide-re-
sistance to the clinical course of S. aureus infections. 
Since almost 20% of patients with nasal colonization by 
MRSA will develop an invasive infection during hospi-
talization, an increase in the prevalence of MRSA will 
likely have a negative impact on public health [119]. 
The invasive potential of VISA or hVISA following 
colonization of the nares will need to be investigated. 
MRSA has been recognized as a public health problem 
in outpatients as well. Several studies have examined the 
clinical impact of S. aureus infections in general, and of 
MRSA infections in injection drug users in particular 
[120–122]. Emergence of VISA or hVISA might further 
complicate the management of infections in this patient 
population. 
Ideally, double-blind, randomized, controlled clinical 
trials would have to be conducted to determine the ap-
proach to the treatment of infections by VISA or hVISA. 
As these infections are still relatively rare, it appears un-
likely that such studies will be realized. However, prospec-
tive clinical studies using clear-cut definitions of resistance, 
predefined clinical endpoints and standardized treatment 
protocols will be needed in order to gain some insight 
into the optimal treatment of such infections. In addition, 
some animal models of infection by glycopeptide-resistant 
S. aureus may be needed in order to determine the role of 
various treatment strategies. As an example, experimen-
tal data, based on models, suggest that lysostaphin or the 
combination with a beta-lactam antibiotic might be alter-
natives to consider for the treatment of infections caused 
by hVISA [123–125].
In conclusion, glycopeptide resistance of S. aureus 
is no longer a theoretical threat. Rather, it is a clinically 
relevant possibility, which should be considered in every 
patient with MRSA infection who shows an unfavorable 
clinical course despite treatment with a glycopeptide. Clini-
cians should be aware of the pathogenesis, epidemiology, 
and clinical consequences of glycopeptide resistance in S. 
aureus, since this pathogen remains one of the most impor-
tant bacteria in modern medicine.
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